Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on September 29, 2021. The filing addresses a material event under Item 8.01 (Other Events) concerning the resolution of a long-standing tax dispute with the Irish Office of the Revenue Commissioners.
Key Financial Metrics and Settlement Terms
The filing details a settlement agreement regarding a Notice of Amended Assessment (NoA) issued in November 2018 related to the 2013 sale of Tysabri intellectual property by Elan Pharma to Biogen Idec.
- Original Claim: Irish Revenue originally claimed €1,636 million in tax payable (excluding interest and penalties).
- Settlement Liability: Perrigo agreed to a total liability of €297 million as a full and final settlement for periods FY13 to FY21.
- Cash Payment: After applying credits for taxes already paid and unused R&D credits, the net cash payment required is €266.1 million.
- Interest and Penalties: The settlement stipulates that no interest is due and no penalties apply.
- Payment Timing: The €266.1 million payment is due within seven days of executing the formal settlement agreement.
Material Changes and Resolution
The settlement resolves a dispute where Irish Revenue argued the Tysabri sale was a capital transaction taxable at 33%, while Perrigo maintained it was a trading transaction taxable at 12.5%. Although Perrigo intended to appeal the NoA to the Irish Tax Appeals Commission, the parties agreed to settle to avoid litigation costs and uncertainty. Irish Revenue has confirmed in writing that it will take no further action regarding the NoA or any Tysabri-related income.
Outlook, Risks, and Management Commentary
Management expects to execute the formal settlement agreement in the coming days. The filing includes standard forward-looking statements regarding the timing of documentation, funding sources, and the benefits of the settlement. Risks identified include the potential for actual results to differ from expectations due to factors beyond the company's control, as detailed in the company's Form 10-K.
Key Facts for Investor Verification
- Verify the execution of the formal settlement agreement with Irish Revenue.
- Confirm the timing and method of the €266.1 million cash outflow.
- Review the impact of the €297 million settlement charge on the company's current quarter earnings and cash flow statements.
- Ensure no further tax assessments or actions are pending regarding the Tysabri transaction.